BTSG vs DGX
BrightSpring Health Services, Inc. and Quest Diagnostics Inc., side by side — 4 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BTSG | DGX |
|---|---|---|
| Revenue | $12.9B | $11.0B |
| Net income | $190.7M | $992.0M |
| Gross margin | 11.8% | 33.2% |
| Net margin | 1.5% | 9.5% |
| Return on equity | 10.8% | 14.2% |
| Diluted EPS | $0.87 | $8.75 |
| Dividend / share | · | · |
| Payout ratio | · | 35.6% |
| Free cash flow | $394.7M | $1.4B |
| Equity | $1.9B | $7.2B |
| Net debt / equity | 1.29× | 0.73× |
| Current ratio | 1.57× | 1.04× |
| Revenue CAGR 5y | · | 3.2% |
| Profit CAGR 5y | · | −7.1% |
BTSG bills 1.2× the revenue of DGX, and DGX keeps more of each dollar of revenue as profit (9.5% against 1.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
4 years side by side
| Fiscal year | BTSG | DGX |
|---|---|---|
| FY2025 | $12.9B | $11.0B |
| FY2024 | $10.1B | $9.9B |
| FY2023 | $7.7B | $9.3B |
| FY2022 | $7.7B | $9.9B |
Bottom line
| Fiscal year | BTSG | DGX |
|---|---|---|
| FY2025 | $190.7M | $992.0M |
| FY2024 | $-18.1M | $871.0M |
| FY2023 | $-154.6M | $854.0M |
| FY2022 | $-53.9M | $946.0M |
Standard deviation, each side
BTSG's net margin has been more volatile than DGX's over the 4 comparable fiscal years — 1.3 percentage points of standard deviation against 0.4.
4 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
DGX led in net margin in every one of the 4 comparable fiscal years — a structural lead, not a recent swing.
4 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BTSG's return on equity has been more volatile than DGX's over the 4 comparable fiscal years — 12.2 percentage points of standard deviation against 0.7.
4 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
DGX led in return on equity in every one of the 4 comparable fiscal years — a structural lead, not a recent swing.
4 of 19 comparable fiscal years — a year missing data on either side is not counted.